Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS
Status:
Not yet recruiting
Trial end date:
2027-08-31
Target enrollment:
Participant gender:
Summary
The TRIPS study is a prospective, multi-center, double-blind, adaptively randomized,
placebo-controlled clinical trial of the drug anakinra for reversal of moderate to severe
hyperinflammation in children with sepsis-induced multiple organ dysfunction syndrome (MODS).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Nationwide Children's Hospital
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)